Last Week in Biomedicine | May 11–15 | Part 2

from Last Week in Biomedicine · host TrialBreaks

Top 10 significant clinical trial results from last weekPart 2:6. Enterprise Therapeutics (private) — ETD001 (inhaled ENaCblocker) for cystic fibrosis (Phase 2)7. Daré Bioscience ($DARE) — Ovaprene (hormone-free monthly intravaginal contraceptive) for contraception (Phase 3)8. Candel Therapeutics ($CADL) — aglatimagene besadenovec (CAN-2409) for localized prostate cancer (Phase 3)9. Alpha Tau Medical ($DRTS) — Alpha DaRT intratumoral alpha-radiotherapy for recurrent glioblastoma (Phase 2)10. IMUNON ($IMNN) — IMNN-001 (IL-12 plasmid gene therapy) for advanced ovarian cancer (Phase 2)Subscribe for weekly clinical trial breakdowns at TrialBreaks.com#biotech #clinicaltrials #pharma #genetherapy #Duchenne #DMD #GLP1 #obesity #oncology #immunotherapy #headandneckcancer #pulmonology #IPF #cysticfibrosis#womenshealth #prostatecancer #glioblastoma #ovariancancer #sleepmedicine

Episode metadata supplied by the publisher feed · Published May 21, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Last Week in Biomedicine | May 11–15 | Part 2

0:00 23:17

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Last Week in Biomedicine?

This episode is 23 minutes long.

When was this Last Week in Biomedicine episode published?

This episode was published on May 21, 2026.

Can I download this Last Week in Biomedicine episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!